- Home
- NAVI vs EYPT Comparison
NAVI vs EYPT Comparison
Compare NAVI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAVI | EYPT |
|---|---|---|
| Founded | 1973 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NAVI | EYPT |
|---|---|---|
| Price | $9.85 | $12.85 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $12.14 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 01-28-2026 | 03-04-2026 |
| Dividend Yield | ★ 6.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,000,000.00 | $42,339,000.00 |
| Revenue This Year | $82.46 | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $3.91 |
| 52 Week High | $16.07 | $19.11 |
Technical Indicators
Market Signals| Indicator | NAVI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 24.06 | 37.22 |
| Support Level | $9.79 | $12.11 |
| Resistance Level | $10.18 | $14.32 |
| Average True Range (ATR) | 0.51 | 1.02 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 17.15 | 17.32 |
Price Performance
Historical ComparisonAbout NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.